Caribou Biosciences is a clinical-stage biopharmaceutical company developing off-the-shelf CAR-T cell therapies using its proprietary chRDNA genome-editing technology to treat blood cancers and solid tumors. The company's lead candidates—vispa-cel for relapsed/refractory B-cell non-Hodgkin lymphoma and CB-011 for relapsed/refractory multiple myeloma—use precision genome edits to enhance immune cell activity and overcome limitations of traditional autologous therapies, including manufacturing cost and treatment duration. Caribou generates value through advancing these therapies toward regulatory approval and commercialization, with strategic partnerships like its arrangement with Pfizer supporting development and bringing products to patients in large, underserved markets.